Neoadjuvant treatment sequencing adds value to the care of patients with operable pancreatic cancer

Elliot A. Asare, Douglas B. Evans, Beth A. Erickson, Murad Aburajab, Parag Tolat, Susan Tsai

Research output: Contribution to journalReview articlepeer-review

Abstract

Treatment sequencing for resectable pancreatic cancer remains controversial and there is lack of level one evidence comparing neoadjuvant versus adjuvant strategies. However, a comparison of the cost-effectiveness analysis of the treatment strategies may help to better define the healthcare value of each approach. This review will highlight the rationale for multimodality therapy in the treatment of pancreatic cancer, discuss the advantages and disadvantages of adjuvant therapy, and conceptualize the cost-effectiveness of a neoadjuvant approach with regard to healthcare value. J. Surg. Oncol. 2016;114:291–295.

Original languageEnglish (US)
Pages (from-to)291-295
Number of pages5
JournalJournal of Surgical Oncology
Volume114
Issue number3
DOIs
StatePublished - Sep 1 2016
Externally publishedYes

Keywords

  • cost-effectiveness
  • healthcare value
  • neoadjuvant therapy
  • pancreatic cancer

ASJC Scopus subject areas

  • Surgery
  • Medicine(all)
  • Oncology

Fingerprint Dive into the research topics of 'Neoadjuvant treatment sequencing adds value to the care of patients with operable pancreatic cancer'. Together they form a unique fingerprint.

Cite this